Evidence map›Paper›PMID 32058016›Full record

ArticleJournal of the American College of Surgeons2020

Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression.

Avinoam Nevler, Samantha Z Brown, David Nauheim, Carla Portocarrero, Ulrich Rodeck, Jonathan Bassig, Christopher W Schultz, Grace A McCarthy, Harish Lavu, Theresa P Yeo and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American College of Surgeons, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Potential of a COMaterials today. Bio · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Avinoam NevlerJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA. Electronic address: Avinoam.nevler@jefferson.edu.
Samantha Z BrownJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
David NauheimSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Carla PortocarreroDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA.
Ulrich RodeckDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA.
Jonathan BassigSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Christopher W SchultzJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Grace A McCarthyJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Harish LavuJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Theresa P YeoJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Charles J YeoJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Jonathan R BrodyJefferson Pancreas, Biliary, and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Thomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9M
NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA212600NCI NIH HHS U01 CA224012
6 · The paper itself

Abstract

backgroundChronic obstructive respiratory disorders (ORDs) are linked to increased rates of cancer-related deaths. Little is known about the effects of hypercapnia (elevated CO STUDY

designTwo PDAC cell lines were exposed to normocapnic (5% CO

resultsExposure to hypercapnia resulted in increased colony formation and proliferation rates in vitro in both cell lines (MIA-PaCa-2: 111% increase and Panc-1: 114% increase; p < 0.05). Hypercapnia exposure induced a 2.5-fold increase in oxaliplatin resistance (p < 0.05) in both cell lines and increased resistance to ionizing radiation in MIA-PaCa-2 cells (p < 0.05). Five hundred and seventy-eight patients were included (52% were male, median age was 68.7 years [interquartile range 60.6 to 76.8 years]). Cox regression analysis, assessing TNM staging, age, sex, and ORD status, identified ORD as an independent risk factor for both overall survival (hazard ratio 1.64; 95% CI, 1.2 to 2.3; p < 0.05) and disease-free survival (hazard ratio 1.68; 95% CI, 1.06 to 2.67).

conclusionsPDAC cells exposed to hypercapnic environments, which is common in patients with ORD, showed tumor proliferation, radioresistance, and chemoresistance. Patients with a history of ORD had a worse overall prognosis, suggesting that hypercapnic conditions play a role in the development and progression of PDAC and stressing the need for patient-tailored care.

Indexed as

Drug Resistance, NeoplasmAgedCarcinoma, Pancreatic DuctalCell Line, TumorCell ProliferationChronic DiseaseDisease ProgressionFemaleHumansHypercapniaLung Diseases, ObstructiveMaleMiddle AgedPancreatic NeoplasmsRetrospective Studies

Identifiers

PMID32058016
PMCPMC7498306
OpenAlexW3004775365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.